Xultophy Expands Label In Europe As First US Approval Decision Looms
Executive Summary
Novo Nordisk has secured a European label extension for its dual type 2 diabetes therapy Xultophy for use in patients with moderate renal impairment – the EU nod is a another boost of confidence the Danish firm needs as it awaits a US regulatory decision.
You may also be interested in...
From Solanezumab To Solithromycin: What To Watch For In Q4
Lilly’s solanezumab, Roche/Genentech’s Ocrevus and Cempra’s solithromycin are among the key therapies scheduled for major data read-outs or approval decisions in Q4 2016. With the help of Informa Pharma Intelligence’s Biomedtracker, Scrip takes a look at what to expect before we enter the new year.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.